Eribulin mesylate has demonstrated clinical benefit as a first-line therapy for locally recurrent or metastatic HER2- negative breast cancer, according to results of a phase II, multicenter, single-arm study.
Significant developments in research and treatment for HER2-positive breast cancer have emerged over the past year. Those advances include a growing number of studies measuring the effectiveness of dual agents.
Previously revealed efficacy data from the BOLERO-3 study indicated slowed tumor progression in patients with trastuzumab-resistant HER2+ breast cancer, and now everolimus, trastuzumab, and vinorelbine has demonstrated a manageable safety profile.
Neoadjuvant and adjuvant therapies, administered before and after primary anticancer therapy, respectively, have been shown in numerous clinical trials to reduce recurrence and improve survival in patients with breast cancer.